Shares of biotechnology company PepGen (NASDAQ:PEPG) are up in the pre-market session today after its lead candidate PGN-ED051 demonstrated promising results in a Phase 1 trial for treating Duchenne Muscular Dystrophy (DMD).
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The drug showed high oligonucleotide delivery and exon skipping and was generally well tolerated. The company now plans to begin a Phase 2a trial in the first half of 2023.
Is PEPG Stock a Buy?
Analysts currently have a Strong Buy consensus rating on PEPG stock with an average price target of $27 which indicates a massive 227.27% potential upside for PepGen Stock.
Read full Disclosure
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue